The European Commission has opened a public consultation on the regulation of CBD in cosmetics, giving formulators, suppliers and industry associations a formal window to weigh in on how cannabidiol should be handled under the EU Cosmetic Products Regulation.

For an industry that has spent years operating in legal ambiguity around cannabinoid ingredients, the consultation marks one of the most concrete procedural steps yet toward clarifying the status of CBD as a cosmetic ingredient in the European market.

Why is the EU consulting now?

The consultation follows sustained pressure from the cannabis and cosmetics sectors to resolve inconsistencies in how CBD is treated across EU member states. Hemp-derived CBD has appeared in skincare, balms and topicals across Europe for years, but the ingredient's regulatory footing has never been fully settled.

The International Cannabis Business Conference, which reported the development, frames the public input exercise as a signal that Brussels is now prepared to engage directly with the question rather than leave it to divergent national interpretations.

For cosmetics businesses, divergence has been the core problem. A CBD-infused cream that clears notification in one member state can face objection in another, complicating pan-EU distribution and forcing brands to fragment their portfolios by geography.

What does the consultation mean for the industry?

A public consultation is not a legislative proposal. It is the evidence-gathering stage that typically precedes one. Industry respondents — ingredient suppliers, cosmetic product responsible persons, testing laboratories and trade associations — can submit positions that will inform the Commission's next steps.

For formulators, the practical stakes include:

• Whether CBD can be listed as a cosmetic ingredient with a defined INCI entry and stable classification
• What purity, traceability and contaminant limits would apply to cannabinoid inputs
• Whether THC trace thresholds will be harmonised across member states
• How safety assessments under Annex I of the Cosmetic Products Regulation should treat cannabinoid chemistry

Procurement teams should note that any resulting clarification would also affect supplier documentation — certificates of analysis, extraction-method disclosures and hemp origin records are all likely to feature in a harmonised regime.

Who should respond?

Public consultations at EU level are open to any interested party, but the submissions that carry the most weight are typically data-rich contributions from companies with market experience and from associations aggregating member evidence. Businesses that have marketed CBD cosmetics in Europe hold the dossiers — safety assessments, consumer exposure data, adverse-event records — that regulators look for when moving from consultation to concrete rules.

Companies that stay silent now should expect to work within rules written by others later. The consultation is the point in the regulatory cycle where the cost of participation is lowest and the influence on outcome is highest.

What comes next?

After the consultation window closes, the Commission will publish a summary of contributions. That summary is the next data point to watch: it will indicate whether the EU leans toward a permissive, ingredient-based framework for CBD cosmetics or a stricter approach that treats cannabinoid inputs as requiring pre-market scrutiny.

Formulators and compliance teams should monitor the Commission's consultation portal for the closing date and the eventual publication of results, and should treat that publication as the trigger for a full review of CBD-containing product portfolios destined for the EU market.